Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

2017, EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis, J Hepatol, 67, 145, 10.1016/j.jhep.2017.03.022 Lindor, 2019, Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 69, 394, 10.1002/hep.30145 Harms, 2018, Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome, Am J Gastroenterol, 113, 254, 10.1038/ajg.2017.440 D'Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, 44, 217, 10.1016/j.jhep.2005.10.013 Harms, 2019, Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis, J Hepatol, 71, 357, 10.1016/j.jhep.2019.04.001 Lammers, 2015, Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy, Gastroenterology, 149, 1804, 10.1053/j.gastro.2015.07.061 2018 Nevens, 2016, A placebo-controlled trial of obeticholic acid in primary biliary cholangitis, N Engl J Med, 375, 631, 10.1056/NEJMoa1509840 Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346 Alempijevic, 2009, Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis, World J Gastroenterol, 15, 591, 10.3748/wjg.15.591 Cheung, 2017, Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis, World J Gastroenterol, 23, 7863, 10.3748/wjg.v23.i44.7863 Trivedi, 2014, Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response, J Hepatol, 60, 1249, 10.1016/j.jhep.2014.01.029 2015, EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006 Carbone, 2018, Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis, Hepatol Commun, 2, 683, 10.1002/hep4.1180 Harms, 2019, Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades, Aliment Pharmacol Ther, 49, 285, 10.1111/apt.15060 Webb, 2018, Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists, Clin Gastroenterol Hepatol, 16, 278, 10.1016/j.cgh.2017.09.062 Honda, 2019, Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis, Hepatology, 70, 2035, 10.1002/hep.30552 Bahar, 2018, Update on new drugs and those in development for the treatment of primary biliary cholangitis, Gastroenterol Hepatol (N Y), 14, 154 Goet, 2018, Risk stratification and prognostic modelling in primary biliary cholangitis, Best Pract Res Clin Gastroenterol, 34–35, 95, 10.1016/j.bpg.2018.06.006